Skip navigation
Image Alt

Know cancer's next move

Signatera is the first and most widely validated tumor-informed assay, specifically designed for molecular residual disease (MRD) monitoring. Learn more about our evolving body of data that was presented at the 2022 ASCO Gastrointestinal Cancers Symposium on January 20-22, 2022.
Contact us for deeper insight into Signatera’s personalized, tumor-informed approach.

We presented two oral presentations to further demonstrate the utility of Signatera in pancreatic and colorectal cancer

Learn about additional validation data underscoring the utility of Signatera in GI Cancers

Increasing levels of ctDNA is strongly associated with poorer patient outcomes

As we have seen in the literature, stage III CRC patients who do not clear their ctDNA after curative intent treatment are likely destined to relapse. These ctDNA positive patients can be further stratified by the rate at which their ctDNA is accelerating. This deeper insight may one day help us determine which patients require urgent intervention to ensure the most favorable outcome.

Industry Expert Theater: Using ctDNA to guide the management of GI cancers

See how a personalized approach to molecular residual disease (MRD) assessment may be used to address the challenges many physicians face when managing their GI cancer patients.

View our latest webinar which takes a closer look at the provocative new data surrounding ctDNA

Our roundtable discussion included insights into common clinical challenges physicians face when managing their patients including:

  • Are clinicopathological features enough to prognosticate recurrence?
  • How can we use ctDNA to catch relapse earlier and potentially improve patient outcomes?
  • What does the recent data tell us about integrating MRD assays into clinical practice?

Learn more

PDF Downloads

Signatera in CRC
Signatera Patient Brochure
How to Order Signatera

PDF Downloads

Bespoke CRC Study Brochure
Signatera Overview in CRC
Signatera in Advanced CRC

Hear the amazing journey of one stage III colorectal cancer patient and how Dr. Kasi used Signatera to inform next steps

Is Signatera right for you?

We’re here to help you find out